Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744 | 1.00 | MEN1 (0.51) | MEN1KMT2AROCK2HIF1ANPC1 | |
| SCHEMBL28622 | 0.92 | KMT2A (0.54) | MEN1KMT2AROCK2HIF1ANPC1 | |
| SCHEMBL30795447 | 0.92 | KMT2A (0.54) | MEN1KMT2AROCK2HIF1ANPC1 | |
| SCHEMBL30795231 | 0.89 | KMT2A (0.61) | MEN1KMT2AROCK2NPC1RAB9A | |
| SCHEMBL713993 | 0.89 | KMT2A (0.61) | MEN1KMT2AROCK2NPC1RAB9A | |
| SCHEMBL30794517 | 0.88 | EGLN1 (0.51) | MEN1KMT2AROCK2HIF1ANPC1 | |
| SCHEMBL29874 | 0.88 | EGLN1 (0.51) | MEN1KMT2AROCK2HIF1ANPC1 | |
| SCHEMBL30794538 | 0.88 | EGLN1 (0.51) | MEN1KMT2AROCK2HIF1ANPC1 | |
| SCHEMBL715292 | 0.86 | ROCK2 (0.48) | MEN1KMT2AROCK2HIF1ANPC1 | |
| SCHEMBL30795780 | 0.86 | ROCK2 (0.48) | MEN1KMT2AROCK2HIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |